Abstracts tagged "infection and inflammatory arthritis"

Abstract Number: 1627 • 2012 ACR/ARHP Annual Meeting
New Insights Into the Presentation and the Management of Hepatitis B Reactivation in Patients with Autoimmune Diseases and Inflammatory Arthritis
Nina Droz¹, Laurent Gilardin², Patrice Cacoub Sr.³, Francis Berenbaum⁴, Daniel Wendling⁵, Bertrand Godeau⁶, Anne-Marie Piette⁷, Emmanuelle Dernis⁸, Mikael Ebbo⁹, Bruno Fautrel¹⁰, Arsène Meikinian¹¹, Aude Rigolet¹², Sophie Rivière¹³, Stanislas Pol¹⁴, Loic Guillevin¹⁵, Luc Mouthon¹⁶ and Benjamin Terrier¹⁷, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Internal Medicine, Saint Antoine Hospital, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ⁵Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁶Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁷Internal Medicine, Foch Hospital, Suresnes, France, ⁸Centre Hospitalier, Le Mans, France, ⁹Internal Medicine, Conception Hospital, Marseille, France, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ¹²Internal Medicine I & II, Pitie-Salpetriere Hospital, APHP, UPMC Paris VI, Paris, France, ¹³Internal Medicine, Lapeyronie, Montpellier, France, ¹⁴Hepatology, Cochin Hospital, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hopital Cochin, Paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: In patients with autoimmune diseases and inflammatory arthritis, immunosuppressive therapy may trigger Hepatitis B virus (HBV) reactivation, leading to significant morbidity and mortality. Objective.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].